

Supplemental Table 1. Association of Baseline Individual Antiretroviral Drug Use with Intermediate-stage Age-related Macular Degeneration in Patients with the Acquired Immune Deficiency Syndrome

Drug	Number patients	AMD *(%)	P-value
Combovir (zidovudine, lamivudine)			0.34
No	1491	9.5	
Yes	333	11.7	
Zidovudine			0.44
No	1757	10.0	
Yes	67	7.5	
Didanosine			0.43
No	1561	10.1	
Yes	263	8.4	
Zalcitabine			0.30
No	1814	9.9	
Yes	10	0	
Stavudine			0.11
No	1340	10.5	
Yes	484	8.1	
Lamivudine			0.90
No	1309	9.8	
Yes	515	9.9	
Abacavir			0.66
No	1528	9.7	
Yes	296	10.8	
Adefovir			0.01
No	1809	9.7	
Yes	15	33.3	
Hydroxyurea			0.35
No	1776	10.0	
Yes	48	6.2	
Tenofovir			0.29
No	1664	9.7	
Yes	160	11.9	
Trizavir (zidovudine, lamivudine, abacavir)			0.51
No	1805	9.9	
Yes	19	5.3	
Epzicom (abacavir, lamivudine)			0.44
No	1782	9.8	
Yes	42	14.3	
Emtricitabine			0.89
No	1816	9.9	
Yes	8	12.5	
Truvada (emtricitabine, tenofovir)			0.61
No	1687	10.0	
Yes	137	8.8	
Atripla (emtricitabine, tenofovir, efavirenz)			NA [†]

No	1824	9.9	
Yes	0	NA	

*AMD = age-related macular degeneration; percent with intermediate-stage AMD reported. †NA = not applicable.